News

As of the data cutoff date, 205 of the 349 patients randomized have experienced disease progression (relapsed) according to investigator determination. Median follow-up for ongoing patients is 31

CR011-vcMMAE is an antibody-drug conjugate comprised of a fully-human monoclonal antibody against glycoprotein NMB (GPNMB) attached to a potent, synthetic drug monomethyl auristatin E (MMAE), using Seattle Genetics’s

Chiral is specialized in research, development and production of active pharmaceutical ingredients (APIs). The acquisition is part of company’s strategy to get direct access to low cost API

Pursuant to the settlement agreement, all claims and appeals by each side will be dismissed following a one-time payment of $3.586 million from Vascular Solutions to Diomed in

Under the terms of the agreement, China Sky One Medical’s wholly-owned subsidiary, Harbin Tian Di Ren Medical Science and Technology Company, acquired 100% of Talon’s outstanding capital stock

The Phase I study will assess safety and tolerability of orally administered ENMD-2076 in refractory cancer patients. In addition, pharmacokinetics will be assessed to determine a dose-dependent response

Four of the first eight patients treated in the study to date have a diagnosis of carcinoma of the head and neck. All three head and neck patients

The study will be performed in collaboration with Cancer Treatment Centers of America (CTCA). Up to 42 eligible patients with stage III or IV ovarian carcinoma will be

The investors in this private placement will also receive five-year warrants to purchase up to seven million additional shares of common stock at an exercise price of $3.75